Financial Data and Key Metrics Changes - System wide sales for Q1 2025 were $132.6 million, up 5% compared to Q1 2024, indicating resilience in the current economic environment [10] - Revenue from continuing operations increased by 7% to $13.1 million from $12.2 million in Q1 2024 [27] - Adjusted EBITDA from continuing operations was $46,000, a significant decrease from $425,000 in Q1 2024 [10][29] - Net loss from continuing operations was $506,000, compared to a loss of $399,000 in Q1 2024 [29] Business Line Data and Key Metrics Changes - Comp sales for all clinics open for at least 13 months were up 3% for Q1 2025 and increased to 4% in March 2025 [10][23] - Comp sales for mature clinics (open for at least 48 months) were down 2% [23] - The company refranchised two corporate clinics and opened five franchise clinics during Q1 2025, with a total of 969 clinics, of which 847 (87%) are franchise clinics [25] Market Data and Key Metrics Changes - The company is experiencing a dynamic consumer environment, with consumer sentiment affecting new patient volumes [11][43] - The company anticipates system wide sales for 2025 to be between $550 million and $570 million, compared to $530.3 million in 2024 [31] Company Strategy and Development Direction - The company aims to become a pure play franchisor, with 93% of corporate clinics under Letters of Intent (LOIs) for refranchising [12][49] - The focus is on strengthening core operations, reigniting growth, and improving profitability through dynamic revenue management and enhanced digital marketing strategies [12][18] - The company plans to launch a new marketing campaign centered around pain relief in the second half of the year [36] Management's Comments on Operating Environment and Future Outlook - Management acknowledges the impact of economic headwinds, inflation, and consumer sentiment on operations but remains optimistic about transitioning to a franchise model [33] - The company expects to see a transformative financial impact as corporate clinics transition to franchise royalties and fees, leading to increased profitability [33] Other Important Information - The company has welcomed new executives to enhance legal strategy and patient experience [39] - The Joint has been recognized as one of the fastest-growing franchises and ranked 37th in the Franchise 500 by Entrepreneur Magazine [40] Q&A Session Summary Question: New patient ad metrics and retention trends - Management noted that new patient volumes have been affected by consumer sentiment, but retention rates remain stable [42][44] Question: Metrics on profitability and overhead reduction - Management is not ready to provide specific metrics but expects profitability to improve as G&A expenses are reduced [45][47] Question: Timeline for refranchising process completion - Management intends to exit 2025 as a pure play franchisor and hopes to accelerate the refranchising process [49] Question: Comp sales performance and strategies for mature clinics - Comp sales for mature clinics have been consistent, and operational strategies will be geared towards strengthening these clinics [80][81] Question: Dynamic pricing impact - Management is exploring various pricing models and anticipates that pricing adjustments could significantly impact total system wide sales [60][62] Question: Selling and marketing expenses normalization - Management expects selling and marketing expenses to normalize by Q3 2025 as the transition to a single marketing agency is completed [66] Question: Cost of the franchisee spring convention - The cost of the convention was lower than previous years, impacting the sales and marketing line [75][76]

Financial Performance - Q1 2025 - Revenue from continuing operations increased by 7% to $131 million compared to $122 million in Q1 2024[33] - Cost of revenue increased by 10% to $30 million [33] - Sales and marketing expenses increased significantly by 57% to $35 million [33] - System-wide sales increased by 5% in Q1 2025 [29] - Comp sales increased by 3% in Q1 2025 [29] - Net loss from continuing operations was $(05) million [33] - Consolidated Adjusted EBITDA was $29 million [33] Liquidity and Cash Flow - Unrestricted cash was $219 million as of March 31 2025 [35] - The company has access to a $20 million line of credit through February 2027 [35, 37] - $37 million was used in operations during the quarter [38] 2025 Guidance - The company reiterates its 2025 guidance for system-wide sales between $550 million and $570 million [39] - The company anticipates mid-single-digit comp sales growth for clinics open 13 months or more [39] - Consolidated Adjusted EBITDA is expected to be between $100 million and $115 million [39]

The Joint Corp. Reports First Quarter 2025 Financial Results - Grew revenue from continuing operations 7% compared to Q1 2024 - - Increased system-wide sales 5% for Q1 2025, demonstrating economic resilience - SCOTTSDALE, Ariz., May 8, 2025 – The Joint Corp. (NASDAQ: JYNT), a national operator, manager, and franchisor of chiropractic clinics, reported its financial results for the quarter ended March 31, 2025. The results of operations of the corporate clinics business segment have been classified as discon ...

Core Insights - The Joint Corp. reported a 7% increase in revenue from continuing operations, reaching $13.1 million in Q1 2025 compared to $12.2 million in Q1 2024, driven by a greater number of franchised clinics [7][8] - System-wide sales increased by 5% to $132.6 million, indicating economic resilience [8] - The company experienced a net loss from continuing operations of $506,000, compared to a loss of $399,000 in the same quarter of the previous year [11] Financial Performance - Adjusted EBITDA for continuing operations was $46,394, down from $424,708 in Q1 2024 [12][37] - Selling and marketing expenses rose to $3.5 million from $2.2 million in Q1 2024, reflecting the costs associated with transitioning to a new marketing team [8][10] - The cost of revenue increased to $3.0 million from $2.7 million, attributed to higher regional developer royalties and commissions [7] Operational Highlights - The company sold 9 franchise licenses in Q1 2025, a decrease from 15 in Q1 2024, due to the refranchising process [9] - Five new franchised clinics were opened, while two corporate clinics were refranchised and one was closed, bringing the total clinic count to 969 [9] - The company aims to enhance its digital marketing and patient experience to drive growth in new clinic openings and system-wide sales [5] Guidance and Future Outlook - The company expects system-wide sales to be between $550 million and $570 million for 2025, compared to $530.3 million in 2024 [19] - Comp sales for clinics open for 13 months or more are projected to be in the mid-single digits, up from 4% in 2024 [19] - Consolidated Adjusted EBITDA is anticipated to be between $10.0 million and $11.5 million, compared to $11.4 million in 2024 [19]

OAKBROOK TERRACE, Illinois, and DENVER, May 08, 2025 (GLOBE NEWSWIRE) -- The Joint Commission and Palantir Technologies announced today a long-term strategic partnership aimed at revolutionizing how healthcare organization and accreditation data are gathered and utilized. This will support healthcare organizations in benchmarking quality and improving outcomes. By leveraging Palantir’s cutting-edge data analytics and artificial intelligence, this collaboration will allow both The Joint Commission and health ...

Group 1 - The Joint Corp. (JYNT) is experiencing significant activity in the options market, particularly with the July 18, 2025 $7.50 Call option showing high implied volatility, indicating potential for a major price movement [1] - Implied volatility reflects market expectations for future stock movement, suggesting that investors anticipate a significant event that could lead to a substantial price change [2] - The Joint currently holds a Zacks Rank 3 (Hold) in the Medical - HMOs industry, which is in the top 27% of the Zacks Industry Rank, but the Zacks Consensus Estimate for the current quarter has shifted from a profit of 2 cents per share to a loss of 2 cents over the last 60 days [3] Group 2 - The high implied volatility surrounding The Joint's options may indicate a developing trading opportunity, as options traders often seek to sell premium on such options to capitalize on time decay [4]

Core Insights - The Joint Corp. is strengthening its leadership team to enhance company core, reignite growth, and improve profitability [1] Leadership Appointments - Andra J. Terrell has been appointed as Senior Vice President Legal, bringing 20 years of experience in franchising legal matters, compliance strategy, and complex transactions [2][5] - Eric Wyatt has been appointed as Senior Vice President Operations and Patient Experience, with over 30 years of experience in franchise operations and general management [4][5] Company Overview - The Joint Corp. is the largest provider of chiropractic care in the U.S., operating over 950 locations and achieving more than 14 million patient visits annually [7] - The company has been recognized in various rankings, including Franchise Times' "Top 400" and "Fast & Serious" lists, and was named "No. 1 in Chiropractic Services" by Entrepreneur [7] Business Structure - The Joint Corp. operates as a franchisor of clinics and provides management services to affiliated chiropractic practices in several states [8]

Company Overview - The Joint Corp. is the largest franchisor of chiropractic care in the United States, operating through The Joint Chiropractic network [5] - The company has over 950 locations nationwide and facilitates more than 14 million patient visits annually [5] - The Joint Corp. has revolutionized access to chiropractic care with a retail healthcare business model introduced in 2010, making quality care convenient and affordable without the need for insurance [5] Industry Context - Arthritis affects over 50 million Americans, with nearly 26 million unable to perform everyday activities due to the condition [1] - Chiropractic care is suggested as a natural method to support long-term joint health and may help reduce inflammation and improve joint function [2][3] - Chronic pain from arthritis can significantly impact mobility and overall well-being, and chiropractic adjustments may alleviate discomfort without prescription medications [3] Treatment and Lifestyle Recommendations - Regular chiropractic adjustments can enhance mobility and manage arthritis-related symptoms effectively [2][3] - Lifestyle changes, such as light exercise, cold therapy, and proper nutrition, are recommended to support joint function and reduce chronic pain [3] Recognition and Achievements - The Joint Corp. is consistently recognized in various industry rankings, including Franchise Times' "Top 400" and "Fast & Serious" lists, and has been named "No. 1 in Chiropractic Services" by Entrepreneur [5] - The company was also listed among the "Top 50 Franchises" in 2024 by SUCCESS [5] Business Structure - The Joint Corp. operates as a franchisor and manages clinics in several states, providing management services to affiliated chiropractic practices [6]

Core Insights - The Joint Corp. has been recognized as one of the 150 fastest-growing franchises by Entrepreneur magazine, ranking No. 37, and has been placed in The 10+ Club for 13 consecutive years [1][2] Company Overview - The Joint Corp. is the largest provider of chiropractic care in the U.S. through The Joint Chiropractic network, operating over 950 locations and facilitating more than 14 million patient visits annually [4] - The company revolutionized access to chiropractic care with its retail healthcare business model introduced in 2010, focusing on convenient and affordable care without the need for insurance [4] Business Model and Services - The Joint Chiropractic offers a no-appointments, no-insurance hassle model, providing affordable chiropractic care with accommodating hours, including evenings and weekends [3] - The company operates as a franchisor of clinics and also manages clinics in certain states, providing management services to affiliated professional chiropractic practices [5] Recognition and Achievements - The Joint has consistently been recognized in various rankings, including being named "No. 1 in Chiropractic Services" by Entrepreneur and appearing on Franchise Times' annual "Top 400" and "Fast & Serious" lists [4] - The fastest-growing ranking is based on net total new franchise units added in the U.S. and Canada from July 2023 to July 2024, with ties broken based on percentage growth [3]

Core Viewpoint - Jet.AI Inc. is forming a joint venture with Consensus Core Technologies Inc. to develop two hyperscale data-center campuses in Canada, aiming to meet the growing demand for AI compute power [1][4] Investment and Financials - Jet.AI plans to invest US $2 million initially, securing a 20% general partner interest and an 8% equity stake in the joint venture, with the option to increase its total commitment to US $20 million [3] - The Midwestern Project currently has 2 MW of capacity, with plans to expand to 100 MW within 12 months, potentially generating an additional $100 million in annual Net Operating Income (NOI) once stabilized [2][4] - The total projected capacity of the joint venture is approximately 1.5 gigawatts, which could equate to around $1.5 billion in NOI as the data centers are constructed and stabilized [4] Project Details - The Midwestern Project is strategically located with a 115 kV transmission line and adjacent to a natural gas pipeline, allowing for immediate power generation capabilities [5] - The Maritime Project has access to high-voltage power and hydro sources, with plans to scale capacity from 40 MW to over 1 gigawatt in the future [6] Strategic Positioning - The joint venture combines Jet.AI's capital markets expertise with Consensus Core's infrastructure development capabilities, positioning it to become a significant player in the AI compute landscape [9] - Consensus Core's experience in developing large-scale infrastructure projects enhances the joint venture's potential to meet the increasing demand for AI data centers [7][8]